Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.51 |
| ▸ | MYC | P01106 | 3/20 | 0.45 |
| ▸ | MAX | P61244 | 3/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 9/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17795679 | 0.93 | EP300 (0.50) | EP300HIF1AARPELP1MYC | |
| SCHEMBL16392556 | 0.93 | EP300 (0.52) | EP300HIF1AARPELP1MYC | |
| SCHEMBL16392496 | 0.90 | AR (0.58) | EP300HIF1AARPELP1MYC | |
| SCHEMBL17795677 | 0.89 | EP300 (0.53) | EP300HIF1AARPELP1MYC | |
| SCHEMBL17795757 | 0.85 | MAPT (0.51) | EP300HIF1AARPELP1KDM4E | |
| SCHEMBL16392551 | 0.85 | AR (0.57) | ARPELP1ABCC1ABCB1KDM4E | |
| SCHEMBL19608100 | 0.85 | EP300 (0.49) | EP300HIF1AABCB1KDM4EMAPT | |
| SCHEMBL17795756 | 0.83 | MAPT (0.52) | EP300HIF1AARPELP1KDM4E | |
| SCHEMBL16392512 | 0.83 | EP300 (0.66) | EP300HIF1AARPELP1MYC | |
| SCHEMBL23739277 | 0.82 | TOP2A (0.42) | EP300KDM4EMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| WO-2016082934-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | SLC7A11, CTH, CBS | EP300 4074/4885HIF1A 2229/4885AR 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.